Short─Term Therapeutic Efficacy of Recombinant Alpha─2b Interferon on Patients with Posttransfusion Hepatitis C

Ｓｈｏｒｔ┐ＴｅｒｍＴｈｅｒａｐｅｕｔｉｃＥｆｆｉｃａｃｙｏｆＲｅｃｏｍｂｉｎａｎｔＡｌｐｈａ┐２ｂＩｎｔｅｒｆｅｒｏｎｏｎＰａｔｉｅｎｔｓｗｉｔｈＰｏｓｔｒａｎｓｆｕｓｉｏｎＨｅｐａｔｉｔｉｓＣＨｕａｎｇＺｕｈｕ（黄祖瑚）ＴａｎｇＢａｏｙｕａｎ（唐...     

抗病毒治疗对慢性丙型肝炎合并冷球蛋白血症患者肝功能的影响

目的：探讨抗病毒治疗对慢性丙型肝炎（ CHC）合并冷球蛋白血症患者肝功能的影响。方法：选取CHC合并冷球蛋白血症患者61例,按是否自愿接受干扰素治疗,分为治疗组33例,对照组28例,治疗组在对照组保肝治疗基础上予以聚乙二醇干扰素α-2a （PEG-IFN-α-2a）联合利巴韦林抗病毒治疗,比较两组患者治疗前、治疗48周及停药后24周各指标的变化。结果：①治疗组患者治疗48周、停药后24周HCV RNA水平低于对照组,差异均有统计学意义（P＜0.05）。②治疗组治疗结束、停药后24周ALT、 TBil低于对照组、 Alb、 PTA含量高于对照组,两组比较差异均有统计学意义（ P＜0.05）。结论：抗病毒治疗可以降低HCV RNA水平并能明显改善CHC合并冷球蛋白血症患者的肝功能。     

Ribavirin and interferon-α combination therapy vs interferon-α alone in the retreatment of chronic hepatitis C: a randomized clinical trial

Interferon-α (IFN-α) induces sustained remission of chronic hepatitisC in approximately 25% of patients. In patients who are non-responders to the first course of therapy, retreatment with IFN-α is of limited efficacy. Ribavirin has also been used to treat chronic hepatitisC, but it induces only a transient response. In this study, we evaluated the efficacy of ribavirin and IFN-α combination therapy for IFN-α resistant chronic hepatitisC. Twenty-four IFN-α non-responders and 24 relapsers were randomized to receive either ribavirin (1000mg per day) together with IFN-α (3–6million units (MU) thrice weekly) or the same dose of IFN-α alone, for 6months. Both at the end of treatment and 6months later, normal transaminase levels were more common in the patients receiving combination therapy than in the group receiving IFN-α alone: 17 (70.8%) vs seven (29.2%) patients ( P =0.009) and six (25%) vs one (4.2%) patient ( P =0.034), respectively. At the end of treatment and 6months later, serum HCV RNA was no longer detectable in eight (33.3%) and five (20.8%) patients in the combination therapy group and in six (25%) and one (4.2%) patient in the IFN-α therapy group, respectively. Three patients (12.5%) were withdrawn prematurely from combination therapy because of side-effects; ribavirin therapy was ceased or dosage reduced in six other patients (25%), again because of side-effects. In conclusion, this combination treatment was more effective than retreatment with IFN-α, alone, in inducing sustained biochemical remission of chronic hepatitisC that was resistant to a previous course of IFN-α. The combination treatment, however, was frequently associated with significant side-effects.     

丙型肝炎患者循环免疫复合物的检测及意义

采用Ｃ１ｑ—ＥｌＬＳＡ法对５１例丙型肝炎（丙肝）患者循环免疫复合物进行了检测，在３４例病人中检出循环免疫复合物（ＣＩＣ）；同时，我们还对丙肝患者免疫球蛋白和补体Ｃ３进行了检测，结果显示丙肝患者ＩｇＧ、ＩｇＭ、ＩｇＡ较正常人升高，而补体Ｃ３下降，提示ＣＩＣ可能在丙肝发病机制中起一定作用